Gene · 3161
Papers2,270
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 2,270
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence. | Dermatol Ther | 2022 | 36200921 | PubTator, text mining | PubMed |
| Screening of the Key Genes for the Progression of Liver Cirrhosis to Hepatocellular Carcinoma Based on Bioinformatics. | J Oncol | 2022 | 36199789 | PubTator, text mining | PubMed |
| Bioinformatic identification of differentially expressed genes associated with hepatocellular carcinoma prognosis. | Medicine (Baltimore) | 2022 | 36197270 | PubTator, text mining | PubMed |
| Enhanced ZNF521 expression induces an aggressive phenotype in human ovarian carcinoma cell lines. | PLoS One | 2022 | 36191006 | PubTator, text mining | PubMed |
| Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers. | J Oncol | 2022 | 36185622 | PubTator, text mining | PubMed |
| Histone methylation modification patterns and relevant M-RiskScore in acute myeloid leukemia. | Heliyon | 2022 | 36164519 | PubTator, text mining | PubMed |
| Visualization of macrophage subsets in the development of the fetal human inner ear. | Front Immunol | 2022 | 36159857 | PubTator, text mining | PubMed |
| Development and validation of an epithelial-mesenchymal transition-related gene signature for predicting prognosis. | World J Clin Cases | 2022 | 36159424 | PubTator, text mining | PubMed |
| The most promising microneedle device: present and future of hyaluronic acid microneedle patch. | Drug Deliv | 2022 | 36151726 | PubTator, text mining | PubMed |
| Biopolymeric Prodrug Systems as Potential Antineoplastic Therapy. | Pharmaceutics | 2022 | 36145522 | PubTator, text mining | PubMed |
| Diverse Roles of the Exon Junction Complex Factors in the Cell Cycle, Cancer, and Neurodevelopmental Disorders-Potential for Therapeutic Targeting. | Int J Mol Sci | 2022 | 36142288 | PubTator, text mining | PubMed |
| AI-assisted discovery of an ethnicity-influenced driver of cell transformation in esophageal and gastroesophageal junction adenocarcinomas. | JCI Insight | 2022 | 36134663 | PubTator, text mining | PubMed |
| Absence of residual tumor tissue after Gamma Knife radiosurgery followed by resection of a vestibular schwannoma: illustrative case. | J Neurosurg Case Lessons | 2022 | 36130577 | PubTator, text mining | PubMed |
| The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes? | J Exp Clin Cancer Res | 2022 | 36114508 | PubTator, text mining | PubMed |
| Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment. | Int J Nanomedicine | 2022 | 36105620 | PubTator, text mining | PubMed |
| Modulating glioblastoma chemotherapy response: Evaluating long non-coding RNA effects on DNA damage response, glioma stem cell function, and hypoxic processes. | Neurooncol Adv | 2022 | 36105389 | PubTator, text mining | PubMed |
| Hyaluronic Acid: A Review of the Drug Delivery Capabilities of This Naturally Occurring Polysaccharide. | Polymers (Basel) | 2022 | 36080515 | PubTator, text mining | PubMed |
| Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells. | Molecules | 2022 | 36080277 | PubTator, text mining | PubMed |
| Multiple Cell Cultures for MRI Analysis. | Int J Mol Sci | 2022 | 36077507 | PubTator, text mining | PubMed |
| The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. | Mol Cancer | 2022 | 36071472 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3161/papers?page=23